source
- FDA approves Takeda’s orexin receptor agonist for narcolepsy, opening new drug classThe FDA has granted approval to Takeda's novel narcolepsy medication, the first orexin receptor agonist to receive clearance. The twice‑daily pill, marketed as Orzeyful, is indicated for narcoleps…
- LifeMine Therapeutics secures $188 million Series E funding from Gates, Bezos and othersLifeMine Therapeutics, a Massachusetts biotech, recently completed a $188 million Series E round, attracting billionaire investors Bill Gates and Jeff Bezos. The funding follows a $75 million Seri…